Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

waterboy182 Oct. 25 at 11:48 PM

$ATOS I cant believe the Dumpster prick is still trolling here. Come on over to $SLS, the water is fine and results by EOY. Thank me later.

1 · Reply

Bunster Oct. 25 at 9:41 PM

$ATOS for mr uber calvee the son of in&out and WB im bullish im bearish im bullish im bearish.ATOS PRICE TARGETS HAVE BEEN MEANINGLE3SS

0 · Reply

CJ27969 Oct. 25 at 8:13 PM

$ATOS $ATOS – Latest Analyst Price Targets (12M) • Ascendiant Capital – Edward Woo: $7.75 (Buy) – 9/22/2025 • H.C. Wainwright – Emily Bodnar: $7.00 (Buy) – 10/07/2025 (reiterated) • Craig-Hallum – Albert Lowe: $4.00 (Buy) – 6/05/2025 (initiation) • Maxim Group – Jason McCarthy: $4.00 (Buy) – 8/14/2025 (maintained) Consensus snapshot (varies by site): avg ≈ $6.25, range $4.00–$7.75 (3–5 analysts)

0 · Reply

The_Real_Heisenberg Oct. 25 at 7:52 PM

$ATOS if MM truly wanted to squeeze retail, they'd have dropped this further or continued to hold it down til the extension date. Thus increasing retails likelihood of selling (weak hands). But they made it compliant now. The company didn't need to do it now, and they've got better news ahead that they seem wildly confident about. Compliance has a significant effect on the ability of bigger fish to buy, and that is the only reason I can think of as to why someone would want this compliant right now instead of later. I.e, big fish are now interested. Large buys are happening. By January 2026, i forsee a real old school run.

2 · Reply

Warrens__Buffet_ Oct. 25 at 5:59 PM

$ATOS fingers crossed for fast track submission news next week! Last week of breast cancer month 🙏🏼🙏🏼

1 · Reply

Henry20feb_ Oct. 25 at 9:35 AM

$ATOS We all welcome Atossa's faster development efforts aimed at addressing more immediate patient needs.👏

0 · Reply

Henry20feb_ Oct. 25 at 9:17 AM

$ATOS Thanks to ChatGPT's scientific analysis of the paradigm-concept.

0 · Reply

Henry20feb_ Oct. 25 at 9:13 AM

$ATOS Atossa's strategic paradigm shift (from a research-driven, long-horizon biotech paradigm to a market-oriented, short-term execution paradigm), takes a while to sink in and materialise. So let's be patient and give them all the support they need!

1 · Reply

Henry20feb_ Oct. 25 at 8:25 AM

$ATOS Next step, back to $ 1 coming week.

0 · Reply

JDAAT Oct. 25 at 2:44 AM

$ATOS at the blue jays game

1 · Reply

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 10 days ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 11 days ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 12 days ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 19 days ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 24 days ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 5 weeks ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 6 weeks ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 2 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 3 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 5 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 5 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 5 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 6 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 6 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 6 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 7 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 7 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 7 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 7 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 8 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 9 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 9 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 9 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 11 months ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 11 months ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 11 months ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 11 months ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 1 year ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 14, 2024, 5:08 PM EDT - 1 year ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 21, 2024, 11:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

Jul 2, 2024, 4:15 PM EDT - 1 year ago

Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer

Jun 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

waterboy182 Oct. 25 at 11:48 PM

$ATOS I cant believe the Dumpster prick is still trolling here. Come on over to $SLS, the water is fine and results by EOY. Thank me later.

1 · Reply

Bunster Oct. 25 at 9:41 PM

$ATOS for mr uber calvee the son of in&out and WB im bullish im bearish im bullish im bearish.ATOS PRICE TARGETS HAVE BEEN MEANINGLE3SS

0 · Reply

CJ27969 Oct. 25 at 8:13 PM

0 · Reply

The_Real_Heisenberg Oct. 25 at 7:52 PM

2 · Reply

Warrens__Buffet_ Oct. 25 at 5:59 PM

$ATOS fingers crossed for fast track submission news next week! Last week of breast cancer month 🙏🏼🙏🏼

1 · Reply

Henry20feb_ Oct. 25 at 9:35 AM

$ATOS We all welcome Atossa's faster development efforts aimed at addressing more immediate patient needs.👏

0 · Reply

Henry20feb_ Oct. 25 at 9:17 AM

$ATOS Thanks to ChatGPT's scientific analysis of the paradigm-concept.

0 · Reply

Henry20feb_ Oct. 25 at 9:13 AM

1 · Reply

Henry20feb_ Oct. 25 at 8:25 AM

$ATOS Next step, back to $ 1 coming week.

0 · Reply

JDAAT Oct. 25 at 2:44 AM

$ATOS at the blue jays game

1 · Reply

Warrens__Buffet_ Oct. 25 at 1:12 AM

$ATOS anyone know when can we expect an announcement or something? Getting pretty dull here.

0 · Reply

Bunster Oct. 25 at 12:22 AM

$ATOS PRIMES WEEK IN REVIEW last week it was compliance compliance. THIS WEEK ITS 93C ON OCTOBER 24 2025 This week we have WB our new bagholding bull.I think formerly a bear last feb then switched to a bull in march saying 2 dollars next week. When that didnt work it was 2 dollars this summer.Then becoming a huge bear for a few months and recently is now a bull again.KNOW YOUR POSTER GIRLS. i think he may be starting to shake and needs daily assurances from rocketboy that we will go up and big.He didnt get the memo that rocketboys nickname is MISS. Raise your hands if u thought and posted last week that this week we will continue to go up. come on dont be shy.

0 · Reply

JDAAT Oct. 24 at 11:10 PM

$ATOS starts curling up

1 · Reply

The_Real_Heisenberg Oct. 24 at 8:55 PM

$ATOS funny, when i first went bearish, the ridicule i received from the bulls was insane. Now i go bullish and everyone gives me lip. Theres no winning on this board lol. Quays made everyone bitter as hell.

4 · Reply

Warrens__Buffet_ Oct. 24 at 8:55 PM

$ATOS when do we moon?

1 · Reply

JDAAT Oct. 24 at 7:43 PM

$ATOS

0 · Reply

Bullrunners Oct. 24 at 6:19 PM

$BURU $SLS $ATOS I love three of them!!!!

0 · Reply

OleGregg Oct. 24 at 5:49 PM

$SLS I hope this doesn't do what it did last after hours Friday...then dump Monday. Big week next week...lets run and hold! $ATOS please be next...please.

2 · Reply

Bullrunners Oct. 24 at 5:17 PM

$SLS $ATOS $BURU I love them all!!!

0 · Reply

Warrens__Buffet_ Oct. 24 at 4:29 PM

$ATOS pushing back to $1!

0 · Reply

DCalcote Oct. 24 at 4:24 PM

$ATOS

0 · Reply

Gwsgws Oct. 24 at 3:59 PM

$ATOS is this the only stock that refuses to rise organically?

1 · Reply

Market Cap	120.41M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	636,900
Avg Vol	905,056
Day's Range	N/A - N/A
Shares Out	129.17M
Stochastic %K	16%
Beta	1.11
Analysts	Sell
Price Target	$5.69